The U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer’s Braftovi combination regimen for the treatment of advanced colon cancer in adults. This approval covers the use of Braftovi (encorafenib) with Eli Lilly’s Erbitux (cetuximab) and standard chemotherapy for patients whose colorectal cancer has spread and who have a specific genetic mutation known as BRAF V600E.
Previously, in December 2024, the FDA had provided accelerated approval for this drug combination after early data indicated promising tumor shrinkage results. On February 24, Pfizer announced that the FDA had now upgraded this to full approval following positive outcomes from a global Phase 3 clinical trial. The study found that patients receiving the combination therapy experienced longer progression-free survival and overall survival compared to those on standard treatment.
According to trial results, patients treated with the new regimen were 51% less likely to die and 47% less likely to experience disease progression or death during the study period than those receiving conventional therapies.
Aamir Malik, Executive Vice President and Chief U.S. Commercial Officer at Pfizer, commented on the decision: “This landmark approval, achieved through the robust clinical benefit demonstrated in the Breakwater trial, validates that this targeted therapy can impact outcomes for people living with an aggressive, hard-to-treat cancer.”
He added: “As the only targeted combination regimen shown to deliver a significant improvement in certain outcomes for patients with BRAF V600E‑mutant metastatic colorectal cancer, Braftovi is uniquely positioned to redefine first‑line treatment and establish a new standard of care.”
Malik also said: “This approval reinforces our leadership in bringing differentiated, potentially practice‑changing cancer therapies to patients and healthcare providers who urgently need improved options.”
Scott Kopetz, M.D., Ph.D., Deputy Chair of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center and co-principal investigator of the Breakwater trial, said: “The Breakwater study demonstrated that these targeted combination regimens provided statistically significant benefit, providing the robust evidence we need to make treatment decisions that can meaningfully impact patient outcomes.” He noted that full FDA approval will give oncologists confidence in using Braftovi plus cetuximab with fluorouracil-based chemotherapy as a first-line option for patients with this mutation.
Colorectal cancer remains one of the most common cancers worldwide and is the second leading cause of cancer-related deaths. Patients carrying the BRAF V600E mutation face more than double the mortality risk compared to those without this genetic change.
